out of stock

Bromazolam is a benzodiazepine derivative, it's a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam, and has similar sedative and anxiolytic effects. Bromazolam is a non subtype selective agonist at the benzodiazepine site of GABAA receptors.

Molecular weight:365.609 g/mol
Compound purity:≥98%
Flubromazolam is reputed to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg. Bromazolam is also known for its strong potency and its long-lasting findings. Experiments typically yield findings of relaxation, euphoria, drowsiness, and stress relief. Bromazolam is currently unscheduled in most nations in the world, making it legal in many places (Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan).
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s
To leave a comment: